With the evolution of biotechnology, addressing allergy treatments for children offers hope for a future where the young can lead lives unrestricted by common food allergens.
A pre-clinical stage Biotech Company aimed to develop its first product for novel food allergy treatment in children through clinical proof of concept before partnering with a global pharmaceutical firm and its currently raising capital to support pre-clinical development program.
With the collaborative assistance of Biointelect, the company’s venture to secure investors was strategically streamlined, ensuring their pioneering approach to children’s food allergy treatments was robustly supported, well-researched, and optimally positioned in the market.
With oncology treatments rapidly growing in interest, the quest to refine and perfect drug delivery mechanisms is paramount. Utilising nanoparticles, a biotech company stands on the verge of reformulating three approved oncology drugs, targeting the expansive US and EU markets.
Biointelect has played a critical role in sculpting the company’s strategy, from inception to investor readiness. It is with Biointelect’s assistance that the biotech company could pivot from concept to a formidable market contender, with a clear and strategic vision for investor engagement.
In the realm of drug and device regulations, having a partner to navigate the complexities can significantly alter a company’s trajectory.
Biointelect collaborated with an early-stage Australian manufacturing firm, crafting a preliminary regulatory strategy for their innovative drug device combination, ensuring they’re not just compliant but also competitive.
At the crossroads of innovation and regulation, the firm sought a strategic compass which they found in Biointelect. This partnership ensured the firm was not only set on a path of compliance but also primed for success in the competitive drug-device landscape.
The landscape of vaccines in Australia is marked by stringent guidelines and a competitive marketplace and above all a focus on patient outcomes.
Biointelect partnered with a pharmaceutical company, well-versed in the Australian market but new to the vaccine domain, to develop a roadmap that would not only introduce their new vaccine but also potentially secure it a coveted position on the National Immunisation Program (NIP) with premium pricing.
In the rapidly evolving world of biotech, adhering to global quality and safety standards is paramount.
A US-based biotech company faced this exact challenge, requiring a Quality Management System (QMS) and Pharmacovigilance (PV) system that would stand up to the exacting standards of major regulatory authorities.
Biointelect collaborated with the client to ensure compliance without compromising efficiency. It was this alignment of expertise and insight that propelled the company to a new level of global operational readiness and compliance.
Introduction The European medical market is the second-largest medical device market following the US, requiring newfound innovation for pharmaceutical companies to reach success. A US Biotech firm, on the cusp of introducing a groundbreaking first-in-class vaccine, sought Biointelect’s expertise to illuminate their path in this intricate and highly saturated market. With Biointelect’s strategic guidance and […]
Antibiotic resistance is a looming global health challenge, with the ESKAPE pathogens leading the charge. Amid this urgent need, a university research group has broken new ground with a patented product that promises to dismantle this resistance.
Biointelect’s partnership was enlisted to bolster their pursuit of the esteemed NHMRC Development Grant, offering an integrated approach leading to a strengthened grant application, optimised strategy, and subsequently, successful grant acquisition.
Introduction As the world delves deeper into the complexities of biotechnology, the need for innovative facilities that can accelerate this progression is paramount. In the heart of this evolution, the NSW Viral Vector Manufacturing Facility stands as a testament to what collaboration and state-of-the-art infrastructure can achieve. Biointelect, as a trusted partner in biotechnological advancements, […]
In an era of rapid advancements in medical technology, the journey to propel RNA therapeutics to the forefront of healthcare solutions is a testament to collaborative innovation.
The NSW Government and the NSW RNA Bioscience Alliance have committed AU$ 96 million to build the RNA pilot facility and an additional AU$ 119 million for operating costs until 2035.
The new facility will conduct small-scale production of messenger RNA (mRNA), synthetic RNA (sRNA) and lipid nanoparticles (LNP) encapsulation at a scale which will enable clinical trials of new therapeutics.
Viruses, cancers, genetic diseases and many other health-related issues are potentially treatable with RNA technologies.
Antimalarial drugs have been instrumental in saving millions of lives. Yet, with the rise of resistance to existing medications, there emerges a critical need for innovative treatments and increased accessibility to newfound medications.
With this difficult mission in mind, US pharmaceutical company 60 Degree Pharmaceuticals (60P) enlisted the strategic service of Biointelect to introduce Tafenoquine (TQ) to the United States and Australian markets.
Through a virtual drug development model, Biointelect’s joint efforts with 60P spanned four years and helped to redefine antimalarial drug availability in these markets. This partnership saw first prophylactic antimalarial drug approval by the FDA and TGA in nearly two decades.